Knowledge of how the immune system recognizes and attempts to control cancer growth and development has improved dramatically. The advent of immunotherapies for cancer has resulted in robust clinical responses and confirmed that the immune system can significantly inhibit tumor progression. Until recently, metastatic melanoma was a disease with limited… (More)
A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies
Bristol-Myers Squibb
Available from: http://clinicaltrials.gov/show…
2013
A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC). Available from: http://clinicaltrials.gov/ct2/show/ NCT00461110
Bristol-Myers Squibb
NLM identifier: NCT00461110. Accessed July
2013
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma or CLL
Bristol-Myers Squibb
Available from: http://clinicaltrials.gov/show…
2013
Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma. Available from: http://clinicaltrials.gov/ct2/ show/NCT00803374. NLM identifier: NCT00803374